Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity

Agonistic 4-1BB antibodies developed for cancer immunotherapy have suffered from either hepatotoxicity or insufficient anti-cancer activity. Here the authors determine the contribution of FcγR binding and agonistic strength to these outcomes, and engineer a 4-1BB antibody with potent anti-tumor effe...

Full description

Saved in:

Bibliographic Details
Main Authors:	Xinyue Qi, Fanlin Li, Yi Wu, Chen Cheng, Ping Han, Jieyi Wang, Xuanming Yang
Format:	article
Language:	EN
Published:	Nature Portfolio 2019
Subjects:	Science Q
Online Access:	https://doaj.org/article/00f1cb7bc64c4223a182e521b81631ef
Tags:	Add Tag No Tags, Be the first to tag this record!

id	oai:doaj.org-article:00f1cb7bc64c4223a182e521b81631ef
record_format	dspace
spelling	oai:doaj.org-article:00f1cb7bc64c4223a182e521b81631ef2021-12-02T14:39:01ZOptimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity10.1038/s41467-019-10088-12041-1723https://doaj.org/article/00f1cb7bc64c4223a182e521b81631ef2019-05-01T00:00:00Zhttps://doi.org/10.1038/s41467-019-10088-1https://doaj.org/toc/2041-1723Agonistic 4-1BB antibodies developed for cancer immunotherapy have suffered from either hepatotoxicity or insufficient anti-cancer activity. Here the authors determine the contribution of FcγR binding and agonistic strength to these outcomes, and engineer a 4-1BB antibody with potent anti-tumor effect and no liver toxicity in mice.Xinyue QiFanlin LiYi WuChen ChengPing HanJieyi WangXuanming YangNature PortfolioarticleScienceQENNature Communications, Vol 10, Iss 1, Pp 1-11 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Xinyue Qi Fanlin Li Yi Wu Chen Cheng Ping Han Jieyi Wang Xuanming Yang Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity
description	Agonistic 4-1BB antibodies developed for cancer immunotherapy have suffered from either hepatotoxicity or insufficient anti-cancer activity. Here the authors determine the contribution of FcγR binding and agonistic strength to these outcomes, and engineer a 4-1BB antibody with potent anti-tumor effect and no liver toxicity in mice.
format	article
author	Xinyue Qi Fanlin Li Yi Wu Chen Cheng Ping Han Jieyi Wang Xuanming Yang
author_facet	Xinyue Qi Fanlin Li Yi Wu Chen Cheng Ping Han Jieyi Wang Xuanming Yang
author_sort	Xinyue Qi
title	Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity
title_short	Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity
title_full	Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity
title_fullStr	Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity
title_full_unstemmed	Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity
title_sort	optimization of 4-1bb antibody for cancer immunotherapy by balancing agonistic strength with fcγr affinity
publisher	Nature Portfolio
publishDate	2019
url	https://doaj.org/article/00f1cb7bc64c4223a182e521b81631ef
work_keys_str_mv	AT xinyueqi optimizationof41bbantibodyforcancerimmunotherapybybalancingagonisticstrengthwithfcgraffinity AT fanlinli optimizationof41bbantibodyforcancerimmunotherapybybalancingagonisticstrengthwithfcgraffinity AT yiwu optimizationof41bbantibodyforcancerimmunotherapybybalancingagonisticstrengthwithfcgraffinity AT chencheng optimizationof41bbantibodyforcancerimmunotherapybybalancingagonisticstrengthwithfcgraffinity AT pinghan optimizationof41bbantibodyforcancerimmunotherapybybalancingagonisticstrengthwithfcgraffinity AT jieyiwang optimizationof41bbantibodyforcancerimmunotherapybybalancingagonisticstrengthwithfcgraffinity AT xuanmingyang optimizationof41bbantibodyforcancerimmunotherapybybalancingagonisticstrengthwithfcgraffinity
_version_	1718390751067373568

Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity

Similar Items